Nothing said here yet.
to join the conversation.
LANXESS has been back in the headlines after Causeway Capital cut its stake while institutions like JPMorgan and UBS disclosed sizeable voting rights, all against a backdrop of ongoing losses and new product plans such as Vulkanox 4060.
LANXESS has seen its share price come under heavy pressure in recent years, which puts a fresh spotlight on whether the current valuation can still be explained by its sales base.
Recent share performance and what it signals LANXESS (XTRA:LXS) has drawn attention after a sharp pullback in recent months, with the share price around €12.21 and declines over the month, past 3 months, year to date, and past year.
The recent cut in LANXESS’ modelled fair value from €16.77 to €15.41 puts the latest price target reset clearly in focus for investors tracking the stock.
LANXESS has seen its share price fall sharply in recent years, which puts fresh focus on whether the current €12.48 level is reasonable when set against its sales.
EQS Voting Rights Announcement: LANXESS Aktiengesellschaft LANXESS AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 09.10.2026 / 18:12 CET/CEST Dissemination of a…
EQS Voting Rights Announcement: LANXESS Aktiengesellschaft LANXESS AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 31.08.2026 / 17:34 CET/CEST Dissemination of a…
EBITDA and cash flow improve on strong working capital management, while management signals confidence in a rebound despite persistent macroeconomic headwinds.